Invitation to attend a Lunchtime Networking Event, Hosted by Merck
We are pleased to be delivering a special lunchtime networking event with OBN Corporate Sponsor, Merck at the Beehouse on Milton Park on 28th November.
The session has been designed to foster collaboration and interaction between professionals and researchers in the fields of drug discovery, biotechnology, and pharmaceutical development, and will start with a short series of presentations addressing the topic of: 'High content screening: From cells to cytokines'.
Presentations will be followed by a delicious lunch over networking and the opportunity to meet with senior members of the Merck team on a 1:1 basis.
Programme:
11.30 Guest arrival and networking
11.45 Keynote presentation One: Dr Alli Lynch: Scientist- Applications and Manufacturing Support
'The limitations of 2D cell culture in drug discovery and the benefits of transitioning to more biologically relevant models'
This talk addresses the limitations of 2D cell culture in drug discovery and the benefits of transitioning to more biologically relevant models. It will highlight how researchers can improve screening outcomes by adopting advanced systems like 2.5D cultures or 3D cultures to better replicate in vivo conditions. Simple adjustments to workflows can enhance biological relevance without adding significant complexity, offering a more predictive approach to drug discovery
12:05 Keynote presentation Two: Dr Aimee Parsons: Scientific Selling Specialist-Biology
'An insight into Luminex xMAP technology and uses for multiplex analysis for a range of biomarkers.'
This talk will cover Luminex xMAP technology for multiplex biomarker analysis and Merck's MILLIPLEX assays, which ensure consistent and reproducible results. We will highlight the MILLIPLEX® PLEXpedition Screening Panel, a versatile kit that enables high-throughput screening of up to 115 analytes, including cytokines, growth factors, and disease-related biomarkers. These kits can be applied across various research areas such as oncology, neuroscience, and cardiovascular research, to name a few. The panel streamlines biomarker discovery and allows seamless transitions to optimised assays for precise protein quantification, accelerating translational and pre-clinical research while saving time and resources.
12.25 Q&A, followed by lunch and networking
13.30 Depart or optional 1:1 Partnering meetings with the Merck team
Who should attend:
This event is designed for professionals and researchers in the fields of drug discovery, biotechnology, and pharmaceutical development interested in meeting the team at Merck and exploring the latest breakthroughs in 3D cell culture and multiplex assay technologies, and how they can accelerate your screening efforts for more accurate and biologically relevant results.
The event is complimentary and available on an 'apply to attend' basis.
About Merck
Merck use the power of leading-edge science to save and improve lives around the world. For more than 130 years, Merck have brought hope to humanity through the development of important medicines and vaccines, They foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.
